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Abstract 
Background 
In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, comparison 
of the effect of fenofibrate on cardiovascular disease (CVD) between those with prior CVD 
and without was a prespecified subgroup analysis. 
Methods 
The effects of fenofibrate on total CVD events and its components in patients who did 
(n=2131) and did not (n=7664) have a history of CVD were computed by Cox proportional-
hazards modeling and compared by testing for treatment-by-subgroup interaction. The 
analyses were adjusted for commencement of statins, use of other CVD medications and 
baseline covariates. Effects on other CVD endpoints were explored. 
Results 
Patients with prior CVD were more likely than those without to be male, to be older (by 3.3 
years), to have had a history of diabetes for 2 years longer at baseline, and to have diabetic 
complications, hypertension, and higher rates of use of insulin and CVD medications. 
Discontinuation of fenofibrate was similar between the subgroups, but more patients with 
prior CVD than without, and also more placebo than fenofibrate-assigned patients, 
commenced statin therapy. The borderline difference in the effects of fenofibrate between 
those who did (HR 1.02; 95% CI, 0.86–1.20) and did not have prior CVD (HR 0.81; 95% 
CI, 0.70–0.94; heterogeneity P=0.045) became nonsignificant after adjustment for baseline 
covariates and other CVD medications (HR 0.96; 95% CI 0.81–1.14 vs HR 0.78; 95% CI 
0.67–0.90) (heterogeneity P=0.06). 
Conclusions 
Our findings do not support treating patients with fenofibrate differently on the basis of any 
history of CVD, in line with evidence from other trials.  
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Introduction 
In people with diabetes, who are already at higher risk of cardiovascular disease (CVD), a 
prior CVD event more than doubles the risk of having a major CVD event and 
approximately triples the risk of cardiovascular death.
1
 
Cholesterol-lowering treatments may be used to modify the characteristic diabetic 
dyslipidemic pattern.
2
 People with type 2 diabetes have low high-density lipoprotein (HDL) 
cholesterol levels and high triglyceride levels,
3, 4
 both of which are associated with higher 
risks of CHD.
5-7
 Fibrates are more effective in reducing triglyceride levels and possibly 
raising HDL cholesterol levels than HMG–CoA reductase inhibitors (statins),8 9 and may 
reduce CVD in people with diabetes.
10-12
 
In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, treatment 
with fenofibrate compared with placebo over an average of 5 years resulted in a 
nonsignificant 11% relative risk reduction (95% CI -5% to 25%) in the primary outcome, 
coronary events (CHD death or nonfatal myocardial infarction).
6
 Fenofibrate treatment 
significantly reduced the prespecified outcome for subgroup comparisons— a composite of 
total CVD events (coronary events, stroke, and coronary and carotid revascularisation) by 
11% (P=0.035).
6
 Subgroup comparisons specified in the main protocol included the effects 
of treatment in patients with a history of CVD compared with patients with no such history. 
Total cardiovascular events were reduced by fenofibrate treatment in those with no prior 
CVD (HR 0.81; 95% CI, 0.70–0.94), but not in those with CVD (HR 1.02; 95% CI, 0.86–
1.20; interaction P=0.045). These results generated considerable discussion. Therefore, this 
paper examines these findings in more detail. 
Methods 
Study design 
Detailed descriptions of the FIELD study design and baseline characteristics have been 
published.
6
 
13
 Between February 1998 and November 2000, people with type 2 diabetes 
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aged between 50 and 75 years were recruited from hospitals and other sources, and 9795 
were randomly allocated to either daily micronised fenofibrate 200 mg (Laboratoires 
Fournier, Dijon, France) or matching placebo. They were followed up for a median of 5 
years.
6
 Lipid criteria for entry to the study included plasma total cholesterol 3.0–6.5 
mmol/L (115–250 mg/dl), plus a total-to-HDL cholesterol ratio 4.0 or plasma triglyceride 
levels of 1.0–5.0 mmol/L (40–195 mg/dl), with no clear indication for or treatment with, 
lipid-modifying therapy at study entry. The study design allowed for the commencement of 
other lipid-lowering therapies during the study at the discretion of the patient’s usual 
physician. Exclusion criteria included renal impairment (serum creatinine >130 
mol/L(1.47 mg/dL)), chronic liver disease, symptomatic gallbladder disease, and any 
CVD event within three months before recruitment. 
The prespecified outcome for subgroup analyses was total CVD, a composite of coronary 
events (CHD death and nonfatal myocardial infarction), stroke, and coronary and carotid 
revascularization. Effects on this composite and its components are presented. 
Patients were categorized as those with and those without CVD before randomization. Prior 
CVD was defined as a reported history of myocardial infarction, stroke, angina (stable or 
unstable), coronary revascularization (coronary artery bypass grafting or percutaneous 
transluminal coronary angioplasty and/or stenting), claudication, peripheral arterial vascular 
disease, or peripheral arterial revascularization. 
All major CVD events and deaths were adjudicated by the Outcomes Assessment 
Committee blinded to treatment allocation and using prespecified definitions. 
The FIELD study was registered as an International Standard Randomised Controlled Trial, 
ISRCTN 64783481. 
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Statistical methods 
For baseline characteristics, categorical outcomes were compared by suitable 2 tests, while 
continuous outcomes were compared by t tests, or if the distribution of the data was non-
normal, the Wilcoxon rank–sum test. 
Change from baseline lipid levels was analyzed using linear models predicting lipid levels 
at 1 year, 2 years, and study close. The baseline lipid level was included as a covariate in 
the model along with CVD group and treatment group. The prior-CVD-by-treatment 
interaction term in the model was tested to determine whether effects of treatment on lipid 
levels differed between those with and those without prior CVD. 
Standard log-rank methods were used without adjustment for covariates to determine the 
statistical significance of the effect of treatment on outcomes within each level of a 
subgroup.
14
 Cox proportional hazards modeling was used to compute the hazard ratio (HR) 
and its 95% confidence intervals (CIs) and to allow adjustment for baseline covariates 
(where specified).
15, 16
 The following baseline covariates were adjusted for: sex, age (in 5-
year groups), diabetes duration (0–2, 3–10, >10 years), smoking status (current vs not 
current), prior cancer, peripheral nerve damage (detected via monofilament test), systolic 
blood pressure (mmHg), total cholesterol (mmol/L), HDL cholesterol (mmol/L), 
hemoglobin A1c (%) and plasma creatinine (mol/L). A test for treatment-by-prior-CVD-
subgroup interaction (heterogeneity) in the proportional-hazards model was performed to 
determine whether the hazard ratio for the effect of treatment on outcome events differed 
according to prior history of CVD.
17, 18
 When this test was no significant, the overall 
estimate of the treatment effect in the combined groups (rather than any subgroup-specific 
estimates) was considered the most valid estimate of treatment efficacy. Although total 
CVD was the prespecified primary endpoint for subgroup analyses, we also included the 
components of total CVD as an exploratory analysis and consider these analyses hypothesis 
generating rather than hypothesis confirming.
18
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We undertook additional analyses incorporating adjustment for nonstudy lipid-lowering 
therapy (statins) and other cardiovascular medications during follow-up because the 
proportions of patients taking these drugs in the two treatment groups were different, as 
were the proportions taking them in the prior-CVD subgroups. Adjustment for the use of 
these medications incorporated a penalized Cox model which adjusted the risk of a CVD 
event occurring individually for the period during which a patient took statins or other 
cardiovascular medications (angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers, beta-blockers, calcium channel blockers, diuretics and antiplatelet 
agents) according to external estimates of their effects on CVD event rates.
19
 Analyses were 
further adjusted for the baseline characteristics previously listed. 
All analyses were according to intention-to-treat to maintain the benefit of a randomized 
comparison. Results were not adjusted for multiple comparisons as outcomes were highly 
correlated.
18
 All analyses used SAS (version 9.2; SAS Institute Inc., Cary, NC, USA). 
Funding and ethical approval 
The FIELD trial was funded by Laboratoires Fournier SA (now part of Abbott ) and grants 
from the National Health and Medical Research Council, Australia.  It was designed by an 
independent management committee, and coordinated by the NHMRC Clinical Trials 
Centre, University of Sydney. All patients provided written informed consent. The study 
protocol was approved by local institutional and national ethics committees and the study 
was performed in accordance with the Declaration of Helsinki and International Conference 
on Harmonisation Good Clinical Practice Guidelines.  
Results 
Baseline characteristics 
Of 9795 patients, 2131 (21.8%) had a history of a prior CVD at baseline. Prior CVD events 
included; myocardial infarction (5.0% of patients), stroke (3.5%), angina (12.1%), and 
coronary revascularization (3.7%). 
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Although the baseline characteristics of the two treatment groups in the main study were 
well matched,
6
 the baseline characteristics of those with and without prior CVD differed 
substantially (Table 1). Participants with prior CVD were more likely to be male, were on 
average 3.3 years older, had a longer average duration of history of diabetes  (2 years 
longer), and were more likely to have microvascular complications of diabetes, to be 
smokers, to have hypertension, and to have high HbA1c, serum creatinine or homocysteine 
levels. Baseline lipid levels in the two groups were statistically significantly different 
although very similar in absolute terms. Those patients with prior CVD were also more 
likely to use insulin, less likely to be managed by diet and had more frequent use of most 
other CVD medications (Table 1). Complete data were available for all variables except 
diabetes duration, which was missing for 17 patients, who were excluded from the 
multivariable analyses. 
Lipids and the effect of fenofibrate treatment 
There were small but statistically significant differences between participants with and 
without prior CVD in their pattern of lipid response to treatment (Figure 1). At 12 months 
after randomization the effect of fenofibrate in raising HDL cholesterol and lowering LDL 
cholesterol and triglyceride levels was greater in those with no prior CVD than in those 
with prior CVD (all P<0.05). At 24 months after randomization, differences in treatment 
effect between prior CVD subgroups were seen for HDL cholesterol (P=0.046) and 
triglycerides (P=0.002). At study close, differences were seen for LDL cholesterol 
(P=0.01) and triglycerides (P=0.006). 
Compliance with trial medication and use of other drugs 
Over the course of the study, those allocated placebo had a higher uptake of lipid-lowering 
therapy (mainly statins) than those allocated fenofibrate (17% and 8%, respectively, 
averaged over the study period). There was also a higher uptake of statins among 
participants with prior CVD than those without and a slightly higher uptake of other CVD 
medications.
6, 13, 19
 Patients with prior CVD discontinued fenofibrate therapy more often 
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than those with no prior CVD (14% and 9%, respectively) (Figure 2). Discontinuing 
fenofibrate because of a possible adverse drug reaction was more common in the subgroup 
with no prior CVD (P<0.001), but discontinuing due to a hospital admission was more 
common in the prior-CVD group (P=0.003). 
Unadjusted effect of treatment on outcomes 
The unadjusted effect of fenofibrate on future total CVD events differed by prior CVD 
status (interaction P=0.05). There was an independently significant reduction in the risk of 
a CVD event (HR 0.81; 95% CI, 0.70–0.94; P=0.004) in the group without prior CVD 
whereas in the prior-CVD group, there was no significant effect of treatment (HR 1.02; 
95% CI, 0.86–1.20, P=0.9).6 
Components of total CVD 
An exploratory analysis of the major components of the total-CVD composite outcome 
showed a statistically significant difference in treatment effect between those with and 
those without prior CVD for coronary events (interaction P=0.03) but not stroke (P=0.56) 
nor revascularization (P=0.053) (Figure 3). For coronary events there was an independently 
significant reduction in the risk of an event (HR 0.75; 95% CI, 0.59–0.94, P=0.01) in the 
group without prior CVD whereas in the prior-CVD group, there was no significant effect 
of treatment (HR 1.08; 95% CI, 0.84–1.38, P=0.55). 
Adjusted analyses of treatment effect 
Even after the adjustment for uneven uptake of statins and other cardiovascular medications 
across treatment arms, the treatment-by-prior-CVD interaction term remained significant 
(statins only P=0.05; statins plus other CVD medications P=0.04) (Figure 4). However, 
after adjustment for baseline covariates, differences in treatment effects were no longer 
apparent (P=0.06). 
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Discussion 
In this prespecified FIELD substudy, fenofibrate reduced total CVD events (the 
prespecified outcome for subgroup analyses) in those patients with no prior history of 
CVD, but did not in patients with a history of CVD before recruitment to the trial. 
However, when the difference between the patient groups with and without prior CVD was 
formally tested for interaction, the difference between them was only marginally 
significant, and was no longer significant after adjustment for baseline covariates. 
Those with prior CVD were more likely to be receiving other CVD medications, including 
statins. Analyses were adjusted to account for differential uptakes of various medications 
on a per patient basis. However, the adjustment for use of statins and other CVD drugs had 
surprisingly little influence on the degree of heterogeneity, so it is unlikely that the 
marginal heterogeneity of treatment effects between prior-CVD subgroups was due to use 
of these other medications. Although those with prior CVD had more risk factors, this was 
not an explanation, as we have established that fenofibrate is equally effective in patients 
with different numbers of (1 to 4) risk factors (data not shown) 
The components of total CVD analyzed in an exploratory analysis were coronary events, 
stroke, and coronary and carotid revascularization. Coronary events and revascularizations 
showed a similar pattern of treatment effects, with greater event reductions in the group 
with no prior CVD; however, only for coronary events were the treatment effects in the 
groups with and without prior CVD statistically different. 
The analysis of prior CVD subgroups was one of 11 subgroup comparisons that were 
predefined.
6
 Although subgroup comparisons were kept to a minimum of clinically 
important factors, and all used the same prespecified composite endpoint, the probability of 
finding at least one false-positive result for heterogeneity of treatment effect was 43%. This 
increased probability of a type I error, combined with the fact that the P value for the 
comparison was only of borderline significance, suggests this result could well be a chance 
finding. 
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Data from other fibrate monotherapy trials do not support lack of benefit in those with a 
history of CVD. The VA-HIT trial in men with prior CHD, low HDL cholesterol and 
normal LDL cholesterol showed that gemfibrozil significantly reduced the risk of CVD 
events (nonfatal myocardial infarction, coronary death, and stroke) by 32% in the 769 with 
diabetes (P=0.004).
12
 In the Helsinki Heart Study, gemfibrozil reduced major coronary 
events (CHD death or nonfatal MI) by 68% in 135 men who had initial 
hypercholesterolemia and no history of CVD, although men with diabetes comprised only 
3% of the study population and the effect in them was not independently significant.
20
 
Furthermore, the ACCORD trial, which examined the effect of fenofibrate in people with 
diabetes on a background of routine open-label statin therapy, also showed no difference in 
treatment effects between those with and those without prior CVD (heterogeneity 
P=0.45),
21
 although there was no significant overall effect on the primary endpoint was 
shown overall. Lastly, a recent meta-analysis showed independently significant benefits of 
fibrate therapy in those with and without prior CVD, without statistical heterogeneity.
22
 
Atherosclerosis develops over decades, and most people with diabetes already have 
subclinical evidence of this at the time their diabetes is diagnosed.
23
 Accordingly, there are 
no particular reasons a priori to expect that the potential effects of an intervention would 
differ between those with or without prior clinical CVD events. On the other hand, because 
fenofibrate is a peroxisome-proliferator agonist and has anti-inflammatory effects as well as 
improving dyslipidemic profiles, larger effects of fenofibrate in those without prior CVD 
related to the role of cardiovascular inflammation are theoretically feasible.
24
 The recent 
meta-analysis of fibrate trials suggested that fibrates may be particularly beneficial for 
patients with high triglyceride and low HDL cholesterol levels, who are at particularly high 
risk of CVD events.
22
 
Introduction of statins during follow-up varied, but measures were introduced to allow for 
this in the statistical analyses. It is possible that the method used to adjust for uptake of 
these drugs did not fully account for its effects. The statin adjustment used independent 
  12 
estimates derived from meta-analyses of large clinical trials;
19
 this method does not 
incorporate possibly different absolute effects of statins in those with diabetes who have 
and have not had CVD.
25
 
In conclusion, statins remain the cornerstone of lipid-modifying therapy in people with 
diabetes. Our detailed analyses showed no evidence of heterogeneity in the effect of 
fenofibrate given as well as statins between  patients who had a history of CVD at baseline 
and those who did not. Patients already taking fenofibrate who have a CVD event may still 
benefit from continuing fenofibrate, particularly if they have elevated triglycerides and low 
HDL levels,
6, 21, 26
 or are at risk of microvascular complications.
21, 27-29
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Figure legends 
Figure 1 
Mean (SE) differences between fenofibrate and placebo in changes from baseline for 
plasma lipid levels, according to prior history of cardiovascular disease (CVD) (solid lines) 
or no prior CVD (dotted lines). Baseline measurements are the mean of Visit 2 (12 weeks 
before randomization) and Visit 3 (6 weeks before randomization), before the run-in on 
active treatment. 
Figure 2 
Average percentages of patients in each treatment arm who commenced other lipid-
lowering treatment (A) or discontinued study treatment (B) per year, by prior CVD status. 
Figure 3 
A. Effects of fenofibrate in patients with prior cardiovascular disease (CVD) (n=2131) and 
without prior CVD (n=7664) on total CVD events, the prespecified composite endpoint for 
subgroup comparisons. 
B. Exploratory analyses of the effects of fenofibrate in patients with and without prior CVD 
for the components of the composite total-CVD endpoint. 
Figure 4 
Effect of fenofibrate on total CVD events in those without and without prior CVD after 
adjustments for uptake of statins, other CVD medications and baseline characteristics. 
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Table 1: Baseline characteristics of patients with and patients without prior CVD 
Characteristics Prior CVD (n=2131) 
No prior CVD 
(n=7664) P* 
General characteristics    
Male (%) 1448 (67.9) 4690 (61.2) <0.001 
Age at Visit 1 (years, mean [SD]) 64.8 (6.5) 61.5 (6.8) <0.001 
Diabetes duration (years, median [IQR]) 7 (3–12) 5 (2–9) <0.001 
Systolic blood pressure (mmHg, mean [SD]) 142.4 (15.6) 139.9 (15.2) <0.001 
Diastolic blood pressure (mmHg, mean [SD]) 81 (8.7) 82 (8.5) <0.001 
Current smoker (%) 242 (11.4) 680 (8.9) <0.001† 
Clinical history (%)    
History of hypertension‡ 1461 (68.6) 4085 (53.3) <0.001 
Microvascular disease‡ 706 (33.1) 1319 (17.2) <0.001 
Laboratory data§    
Total cholesterol (mmol/L, mean [SD]) 4.98 (0.69) 5.05 (0.71) <0.001 
 (mg/dL, mean [SD])) 192 (27) 195 (27)  
LDL cholesterol (mmol/L, mean [SD]) 3.03 (0.65) 3.08 (0.65) 0.002 
 (mg/dL, mean [SD])) 117 (25) 119 (25)  
HDL cholesterol (mmol/L, mean [SD]) 1.06 (0.25) 1.11 (0.26) <0.001 
 (mg/dL, mean [SD])) 41 (10) 43 (10)  
Triglyceride (mmol/L, median [IQR]) 1.79 (1.35–2.40) 1.72 (1.34–2.30) 0.009 
 (mg/dL, mean [SD])) 158 (119–212) 152 (119–204)  
Hemoglobin A1c (%, median [IQR]) 7.0 (6.3–8.0) 6.8 (6.1–7.7) <0.001 
Baseline cardiovascular medication (%)    
Antiplatelets (including aspirin) 1222 (57.3) 1633 (21.3) <0.001 
ACE Inhibitors 882 (41.4) 2399 (31.3) <0.001 
Angiotensin II receptor antagonist 107 (5.0) 415 (5.4) 0.47 
Beta blocker 616 (28.9) 806 (10.5) <0.001 
Calcium antagonists 656 (30.8) 1236 (16.1) <0.001 
Nitrate 510 (23.9) 40 (0.5) <0.001 
Diuretic 475 (22.3) 1010 (13.2) <0.001 
Baseline blood-glucose-lowering medication (%)   
Diet alone 432 (20.3) 2176 (28.4) <0.001 
Metformin alone 321 (15.1) 1400 (18.3) <0.001 
Insulin (± oral agents) 412 (19.3) 934 (12.2) <0.001 
*  P value from chi-square test for categorical variables, t test for normally distributed continuous 
variables or Wilcoxon rank–sum test for non-normally distributed continuous variables. 
†  P value for smoking status (current, ex-smoker or never smoked) from 3 x 2 chi-square test. 
‡ Self reported at Visit 1 
§ Mean of Visit 2 and Visit 3, except for HbA1c and creatinine (mean of Visit 1 and Visit 3) and 
homocysteine (Visit 3) 
CVD = cardiovascular disease; SD = standard deviation; IQR = interquartile range; LDL = low-density 
lipoprotein; HDL = high-density lipoprotein 
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Table 1: Baseline characteristics of patients with and patients without prior CVD 
Characteristics Prior CVD (n=2131) 
No prior CVD 
(n=7664) P* 
General characteristics    
Male (%) 1448 (67.9) 4690 (61.2) <0.001 
Age at Visit 1 (years, mean [SD]) 64.8 (6.5) 61.5 (6.8) <0.001 
Diabetes duration (years, median [IQR]) 7 (3–12) 5 (2–9) <0.001 
Systolic blood pressure (mmHg, mean [SD]) 142.4 (15.6) 139.9 (15.2) <0.001 
Diastolic blood pressure (mmHg, mean [SD]) 81 (8.7) 82 (8.5) <0.001 
Current smoker (%) 242 (11.4) 680 (8.9) <0.001† 
Clinical history (%)    
History of hypertension‡ 1461 (68.6) 4085 (53.3) <0.001 
Microvascular disease‡ 706 (33.1) 1319 (17.2) <0.001 
Laboratory data§    
Total cholesterol (mmol/L, mean [SD]) 4.98 (0.69) 5.05 (0.71) <0.001 
 (mg/dL, mean [SD])) 192 (27) 195 (27)  
LDL cholesterol (mmol/L, mean [SD]) 3.03 (0.65) 3.08 (0.65) 0.002 
 (mg/dL, mean [SD])) 117 (25) 119 (25)  
HDL cholesterol (mmol/L, mean [SD]) 1.06 (0.25) 1.11 (0.26) <0.001 
 (mg/dL, mean [SD])) 41 (10) 43 (10)  
Triglyceride (mmol/L, median [IQR]) 1.79 (1.35–2.40) 1.72 (1.34–2.30) 0.009 
 (mg/dL, mean [SD])) 158 (119–212) 152 (119–204)  
Hemoglobin A1c (%, median [IQR]) 7.0 (6.3–8.0) 6.8 (6.1–7.7) <0.001 
Baseline cardiovascular medication (%)    
Antiplatelets (including aspirin) 1222 (57.3) 1633 (21.3) <0.001 
ACE Inhibitors 882 (41.4) 2399 (31.3) <0.001 
Angiotensin II receptor antagonist 107 (5.0) 415 (5.4) 0.47 
Beta blocker 616 (28.9) 806 (10.5) <0.001 
Calcium antagonists 656 (30.8) 1236 (16.1) <0.001 
Nitrate 510 (23.9) 40 (0.5) <0.001 
Diuretic 475 (22.3) 1010 (13.2) <0.001 
Baseline blood-glucose-lowering medication (%)   
Diet alone 432 (20.3) 2176 (28.4) <0.001 
Metformin alone 321 (15.1) 1400 (18.3) <0.001 
Insulin (± oral agents) 412 (19.3) 934 (12.2) <0.001 
*  P value from chi-square test for categorical variables, t test for normally distributed continuous 
variables or Wilcoxon rank–sum test for non-normally distributed continuous variables. 
†  P value for smoking status (current, ex-smoker or never smoked) from 3 x 2 chi-square test. 
‡ Self reported at Visit 1 
§ Mean of Visit 2 and Visit 3, except for HbA1c and creatinine (mean of Visit 1 and Visit 3) and 
homocysteine (Visit 3) 
CVD = cardiovascular disease; SD = standard deviation; IQR = interquartile range; LDL = low-density 
lipoprotein; HDL = high-density lipoprotein 
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